journal article·2025-01-06Open access

From Blood to Therapy: The Revolutionary Application of Platelets in Cancer-Targeted Drug Delivery

Lijuan Xie, Fengxu Gan, Yun Hu, Yibin Zheng, Junshan Lan, Yuting Liu, Xiaofang Zhou, Jianyu Zheng, Xing Zhou, Jie Lou

Abstract

Biomimetic nanodrug delivery systems based on cell membranes have emerged as a promising approach for targeted cancer therapy due to their biocompatibility and low immunogenicity. Among them, platelet-mediated systems are particularly noteworthy for their innate tumor-homing and cancer cell interaction capabilities. These systems utilize nanoparticles shielded and directed by platelet membrane coatings for efficient drug delivery. This review highlights the role of platelets in cancer therapy, summarizes the advancements in platelet-based drug delivery systems, and discusses their integration with other cancer treatments. Additionally, it addresses the limitations and challenges of platelet-mediated drug delivery, offering insights into future developments in this innovative field.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China

Chongqing Key Laboratory of Medicinal Chemistry and Molecular Pharmacology, Chongqing University of Technology, Chongqing 400054, China

Yunnan Key Laboratory of Stem Cell and Regenerative Medicine, School of Rehabilitation, Kunming Medical University, Kunming 650500, China

Funding

Chongqing University of Technology National Fund Cultivation Project · Science and Technology Research Program of Chongqing Municipal Education Commission · Funding results of Action plan for high-quality Development of graduate education of Chongqing University of Technology

References (100+)

Show source-provided references
1. Recent trends in cancer therapy: A review on the current state of gene delivery10.1016/j.lfs.2021.119087 ↗
2. What Is Cancer?10.1353/pbm.2019.0046 ↗
3. Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure10.1038/s41588-020-0708-0 ↗
4. Hallmarks of Cancer: New Dimensions10.1158/2159-8290.CD-21-1059 ↗
5. Global cancer statistics, 201210.3322/caac.21262 ↗
6. Recent advances in tumor-targeting anticancer drug conjugates10.1016/j.bmc.2005.04.084 ↗
7. Cancer immunotherapy: An evolving paradigm10.1631/jzus.B2210001 ↗
8. Recent advances in cell membrane coated metal-organic frameworks (MOFs) for tumor therapy10.1039/D1TB00453K ↗
9. Emerging Approaches to Functionalizing Cell Membrane-Coated Nanoparticles10.1021/acs.biochem.0c00343 ↗
10. Wu, X., Li, Y., Raza, F., Wang, X., Zhang, S., Rong, R., Qiu, M., and Su, J. (2021). Red Blood Cell Membrane-Camouflaged Tedizolid Phosphate-Loaded PLGA Nanoparticles for Bacterial-Infection Therapy. Pharmaceutics, 13.10.3390/pharmaceutics13010099 ↗
11. Cell membrane-coated nanocarriers: The emerging targeted delivery system for cancer theranostics10.1016/j.drudis.2018.02.001 ↗
12. From bench to bedside: Platelet biomimetic nanoparticles as a promising carriers for personalized drug delivery10.1016/j.jconrel.2024.07.013 ↗
13. Zhu, Y., Xu, L., Kang, Y., Cheng, Q., He, Y., and Ji, X. (2024). Platelet-derived drug delivery systems: Pioneering treatment for cancer, cardiovascular diseases, infectious diseases, and beyond. Biomaterials, 306.10.1016/j.biomaterials.2024.122478 ↗
14. Platelets for advanced drug delivery in cancer10.1080/17425247.2023.2217378 ↗
15. Seminars in Thrombosis and Hemostasis10.1055/s-2007-1004999 ↗
16. The incredible journey: From megakaryocyte development to platelet formation10.1083/jcb.201304054 ↗
17. Combination of drugs and carriers in drug delivery technology and its development10.2147/DDDT.S198056 ↗
18. Normal platelet function10.1007/s10555-017-9677-x ↗
19. Platelets, petechiae, and preservation of the vascular wall10.1056/NEJMra0800887 ↗
20. Platelets and Platelet-Inspired Biomaterials Technologies in Wound Healing Applications10.1021/acsbiomaterials.7b00013 ↗
21. Platelet integrin αIIbβ3: Signal transduction, regulation, and its therapeutic targeting10.1186/s13045-019-0709-6 ↗
22. Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis10.1016/j.thromres.2009.11.023 ↗
23. The role of platelets in immune-mediated inflammatory diseases10.1038/s41577-023-00834-4 ↗
24. Platelet Function in Thrombosis and Hemostasis10.1055/s-0036-1572329 ↗
25. Mandel, J., Casari, M., Stepanyan, M., Martyanov, A., and Deppermann, C. (2022). Beyond Hemostasis: Platelet Innate Immune Interactions and Thromboinflammation. Int. J. Mol. Sci., 23.10.3390/ijms23073868 ↗
26. Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases10.1124/pr.117.014530 ↗
27. Current applications of platelet gels in wound healing—A review10.1111/wrr.12896 ↗
28. NCK-dependent pericyte migration promotes pathological neovascularization in ischemic retinopathy10.1038/s41467-018-05926-7 ↗
29. Small but mighty: Platelets as central effectors of host defense10.1160/TH16-12-0921 ↗
30. The Immune Nature of Platelets Revisited10.1016/j.tmrv.2020.09.005 ↗
31. Antimetastatic effects associated with platelet reduction10.1073/pnas.61.1.46 ↗
32. Johnson, K.E., McAllister, S.S., Italiano, J.E., and Battinelli, E.M. (2022). The Role of Platelets in the Tumor Microenvironment. Biomarkers of the Tumor Microenvironment, Springer.
33. Involvement of Platelet-Derived Microparticles in Tumor Progression and Thrombosis10.1053/j.seminoncol.2014.04.010 ↗
34. Yu, L., Guo, Y., Chang, Z., Zhang, D., Zhang, S., Pei, H., Pang, J., Zhao, Z.J., and Chen, Y. (2021). Bidirectional Interaction Between Cancer Cells and Platelets Provides Potential Strategies for Cancer Therapies. Front. Oncol., 11.10.3389/fonc.2021.764119 ↗
35. Paraneoplastic syndromes of leukocytosis, thrombocytosis, and hypercalcemia associated with squamous cell carcinoma10.1111/j.1346-8138.1999.tb03487.x ↗
36. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis10.1016/S0002-9343(99)80013-8 ↗
37. Thrombocytosis in patients with tumors producing colony-stimulating factor10.1182/blood.V80.8.2052.2052 ↗
38. Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors10.1182/blood.V86.9.3353.bloodjournal8693353 ↗
39. Increased secretion of interleukin-6 in malignant mesothelioma cells from a patient with marked thrombocytosis10.1002/1097-0142(19921015)70:8<2105::AID-CNCR2820700816>3.0.CO;2-R ↗
40. Paraneoplastic thrombocytosis: The secrets of tumor self-promotion10.1182/blood-2014-03-562538 ↗
41. A novel and essential role for FcγRIIa in cancer cell-induced platelet activation10.1182/blood-2013-03-492447 ↗
42. Pathophysiology of the thrombophilic state in the cancer patient10.1055/s-2007-994919 ↗
43. Platelets and cancer angiogenesis nexus10.1007/s10555-017-9673-1 ↗
44. Platelets and (Lymph)angiogenesis10.1101/cshperspect.a041174 ↗
45. Hu, C., Long, L., Lou, J., Leng, M., Yang, Q., Xu, X., and Zhou, X. (2024). CTC-neutrophil interaction: A key driver and therapeutic target of cancer metastasis. Biomed. Pharmacother., 180.10.1016/j.biopha.2024.117474 ↗
46. Introduction to a review series on platelets and cancer10.1182/blood.2020010237 ↗
47. Neutrophil Nanodecoys Inhibit Tumor Metastasis by Blocking the Interaction between Tumor Cells and Neutrophils10.1021/acsnano.3c08946 ↗
48. Blocking podoplanin inhibits platelet activation and decreases cancer-associated venous thrombosis10.1016/j.thromres.2021.01.008 ↗
49. Lysis of tumor cells by natural killer cells in mice is impeded by platelets
50. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity10.1158/0008-5472.CAN-09-2123 ↗
51. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells10.1158/0008-5472.CAN-11-1872 ↗
52. Mechanistic explanation for platelet contribution to cancer metastasis10.1016/S0049-3848(14)50025-4 ↗
53. Platelet RNA signatures for the detection of cancer10.1007/s10555-017-9674-0 ↗
54. mTORC1 promotes aging-related venous thrombosis in mice via elevation of platelet volume and activation10.1182/blood-2015-10-672964 ↗
55. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS)10.1182/blood-2008-02-142422 ↗
56. Rethinking the war on cancer
57. New insights in synovial angiogenesis10.1016/j.jbspin.2009.05.011 ↗
58. Breakdown of the endothelial barrier function in tumor cell transmigration10.1529/biophysj.107.113613 ↗
59. Cancer cells regulate biomechanical properties of human microvascular endothelial cells10.1074/jbc.M111.256172 ↗
60. Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets10.1124/mol.112.083477 ↗
61. Anti-inflammatory mechanisms of neutrophil membrane-coated nanoparticles without drug loading10.1016/j.jconrel.2024.03.030 ↗
62. Fang, M., Liu, R., Fang, Y., Zhang, D., and Kong, B. (2024). Emerging platelet-based drug delivery systems. Biomed. Pharmacother., 177.10.1016/j.biopha.2024.117131 ↗
63. Platelet CD47 Maintains Circulating Monocyte Immune Homeostasis10.1182/blood-2023-179997 ↗
64. Platelet collagen receptors and their role in modulating platelet adhesion patterns and activation on alternatively processed collagen substrates10.1016/j.thromres.2024.109201 ↗
65. Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9
66. Tumors and Fibrinogen
67. The role of P-selectin in cancer-associated thrombosis and beyond10.1016/j.thromres.2021.12.027 ↗
68. Single-molecule binding of CD44 to fibrin versus P-selectin predicts their distinct shear-dependent interactions in cancer10.1242/jcs.079814 ↗
69. Advances of blood cell-based drug delivery systems10.1016/j.ejps.2016.07.021 ↗
70. Xu, P., Zuo, H., Chen, B., Wang, R., Ahmed, A., Hu, Y., and Ouyang, J. (2017). Doxorubicin-loaded platelets as a smart drug delivery system: An improved therapy for lymphoma. Sci. Rep., 7.10.1038/srep42632 ↗
71. A Platelet Intelligent Vehicle with Navigation for Cancer Photothermal-Chemotherapy10.1021/acsnano.2c00453 ↗
72. Platelets are highly efficient and efficacious carriers for tumor-targeted nano-drug delivery10.1080/10717544.2022.2053762 ↗
73. Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and Thrombus10.1002/adma.201603463 ↗
74. Nanoparticle biointerfacing by platelet membrane cloaking10.1038/nature15373 ↗
75. pH-responsive hybrid platelet membrane-coated nanobomb with deep tumor penetration ability and enhanced cancer thermal/chemodynamic therapy10.7150/thno.68996 ↗
76. Magnetic Metal-Organic Framework-Based Nanoplatform with Platelet Membrane Coating as a Synergistic Programmed Cell Death Protein 1 Inhibitor against Hepatocellular Carcinoma10.1021/acsnano.3c07885 ↗
77. Platelets and extracellular vesicles and their cross talk with cancer10.1182/blood.2019004119 ↗
78. Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy10.1038/s41551-018-0310-2 ↗
79. Genetic engineering of platelets to neutralize circulating tumor cells10.1016/j.jconrel.2016.02.036 ↗
80. Glycopolymeric Micellar Nanoparticles for Platelet-Mediated Tumor-Targeted Delivery of Docetaxel for Cancer Therapy10.1021/acsami.4c09548 ↗
81. Anticancer Platelet-Mimicking Nanovehicles10.1002/adma.201503323 ↗
82. Wang, H., Wu, J., Williams, G.R., Fan, Q., Niu, S., Wu, J., Xie, X., and Zhu, L.M. (2019). Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery. J. Nanobiotechnol., 17.10.1186/s12951-019-0494-y ↗
83. Cancer nanomedicine: Progress, challenges and opportunities10.1038/nrc.2016.108 ↗
84. Combining antiangiogenics to overcome resistance: Rationale and clinical experience10.1158/1078-0432.CCR-11-1275 ↗
85. Antiangiogenic therapy for cancer: An update10.1002/phar.1147 ↗
86. Platelet-Membrane-Coated Nanoparticles Enable Vascular Disrupting Agent Combining Anti-Angiogenic Drug for Improved Tumor Vessel Impairment10.1021/acs.nanolett.1c00168 ↗
87. Leukemia regression by vascular disruption and antiangiogenic therapy10.1182/blood-2009-06-230474 ↗
88. Platelet Membrane-Camouflaged Magnetic Nanoparticles for Ferroptosis-Enhanced Cancer Immunotherapy10.1002/smll.202001704 ↗
89. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors10.1038/s41467-021-22311-z ↗
90. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets10.1038/s41551-021-00712-1 ↗
91. Platelets camouflaged nanovehicle improved bladder cancer immunotherapy by triggering pyroptosis10.7150/thno.99040 ↗
92. Platelet membrane biomimetic nanomedicine induces dual glutathione consumption for enhancing cancer radioimmunotherapy10.1016/j.jpha.2024.01.003 ↗
93. Gene therapy: A double-edged sword with great powers10.1007/s11010-020-03834-3 ↗
94. Targeted gene silencing in vivo by platelet membrane-coated metal-organic framework nanoparticles10.1126/sciadv.aaz6108 ↗
95. Platelet-Like Fusogenic Liposome-Mediated Targeting Delivery of miR-21 Improves Myocardial Remodeling by Reprogramming Macrophages Post Myocardial Ischemia-Reperfusion Injury10.1002/advs.202100787 ↗
96. Camouflaged Hybrid Cancer Cell-Platelet Fusion Membrane Nanovesicles Deliver Therapeutic MicroRNAs to Presensitize Triple-Negative Breast Cancer to Doxorubicin10.1002/adfm.202103600 ↗
97. Membrane-wrapped nanoparticles for photothermal cancer therapy10.1186/s40580-022-00328-4 ↗
98. Platelet-mimicking nanoparticles co-loaded with W(18)O(49) and metformin alleviate tumor hypoxia for enhanced photodynamic therapy and photothermal therapy10.1016/j.actbio.2018.09.017 ↗
99. NIR light-induced tumor phototherapy using ICG delivery system based on platelet-membrane-camouflaged hollow bismuth selenide nanoparticles10.1016/j.cclet.2019.10.040 ↗
100. Platelet-membrane-camouflaged bismuth sulfide nanorods for synergistic radio-photothermal therapy against cancer10.1039/C9BM00599D ↗